HemoSonics’ Quantra Hemostasis System Shines in TIME’s 2024 Best Inventions
HemoSonics, a prominent medical device company specializing in acute bleeding management, has recently earned recognition in TIME's 2024 Best Inventions List. This prestigious list honors innovations that are making a significant impact on the world, and HemoSonics’ Quantra Hemostasis System was given a Special Mention for its exceptional contributions.
Introducing the Quantra Hemostasis System
The Quantra Hemostasis System is designed to deliver rapid, comprehensive blood analysis, offering crucial insights into hemostatic function in under 15 minutes. This system encompasses the Quantra Hemostasis Analyzer along with QPlus and QStat Cartridges, enabling clinicians to make informed decisions regarding bleeding management. By optimizing blood product usage, HemoSonics helps improve patient-centered care.
Innovative Technology Behind the System
At the heart of the Quantra System is the revolutionary SEER Sonorheometry technology, which stands for Sonic Estimation of Elasticity via Resonance. This proprietary ultrasound technology measures the coagulation properties of whole blood, providing healthcare professionals with the necessary data to assess patients' bleeding status effectively and efficiently. Typically, clinicians can expect results in less than 15 minutes, which is crucial during critical surgical and medical procedures.
Regulatory Approvals and Clinical Applications
HemoSonics’ Quantra System is FDA-cleared for use in various high-stakes medical scenarios, including cardiovascular surgery, trauma, liver transplantation, and major orthopedic surgery. Its user-friendly design ensures minimal training is required for operators, making it an ideal tool for both point-of-care and laboratory settings.
Response to Recognition
Bob Roda, President and CEO of HemoSonics, expressed his pride in the company’s achievements. "Receiving recognition from TIME is a significant honor for us. We strive to innovate and improve patient care, ensuring that individuals receive timely and appropriate treatment during critical moments in their healthcare journey," he remarked.
Recent Developments
In addition to this recent accolade, HemoSonics announced earlier this year that they obtained Special 510(k) clearance from the FDA. This approval allows for the expanded use of arterial blood samples with their QStat Cartridge, complementing the previously established venous whole blood sample capabilities. The company is constantly evolving to meet the needs of healthcare providers and improve patient outcomes.
Winning Awards and Recognition
The company was also honored with a RADx award recently, recognizing its efforts in supporting research initiatives that aim to assist obstetric patients. This reflects HemoSonics’ dedication to addressing various facets of acute bleeding management across multiple medical disciplines.
The Selection Process
TIME's selection process for its annual Innovations List involved soliciting nominations from editors and correspondents worldwide. Emphasizing the importance of originality, efficacy, ambition, and impact, TIME highlights innovations that may change the landscape of technology and healthcare.
What TIME Said About the List
The editors at TIME noted, "This year's list includes 200 groundbreaking inventions that redefine our perspectives on living and working, such as bioluminescent houseplants and sophisticated AI applications." The Special Mentions, including HemoSonics’ Quantra System, signify advancements that are crucial in improving health outcomes.
About HemoSonics
HemoSonics is dedicated to enhancing acute bleeding management through cutting-edge medical technology. The flagship Quantra Hemostasis Analyzer serves as a vital tool that aids in optimizing blood coagulation information, ultimately improving patient care and minimizing healthcare costs. Their aim is to deliver simple yet effective solutions for clinicians in both urgent and routine settings.
Headquartered in Durham, North Carolina, HemoSonics operates under the Stago Group, which specializes in in vitro diagnostics and is committed to advancing the field of thrombosis and hemostasis. For more information about their innovative solutions, visit HemoSonics.com.
Frequently Asked Questions
What is the Quantra Hemostasis System?
The Quantra Hemostasis System is a medical device that provides quick and comprehensive blood analysis for bleeding management in critical medical situations.
How fast does the Quantra System provide results?
The system typically delivers results in less than 15 minutes, which is essential for timely clinical decision-making.
Is the Quantra System FDA-approved?
Yes, the Quantra System is FDA-cleared for various surgical applications including cardiovascular and orthopedic surgeries.
What recent accolades has HemoSonics received?
HemoSonics recently received a Special Mention in TIME's 2024 Best Inventions List and a RADx award for its contributions to healthcare innovations.
What technology is behind the Quantra System?
The Quantra System utilizes SEER Sonorheometry, a proprietary ultrasound technology that assesses the coagulation properties of whole blood.
